Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) Chief Medical Officer Dr. Islam Mohamed appeared on the IBN BioMedWire Podcast to discuss the company's lead drug candidate ONC010 and its novel approach to targeting the DNA repair enzyme polynucleotide kinase phosphatase (PNKP), according to a recent announcement. The podcast also covered the company's planned first-in-human clinical program for the drug candidate.
During the interview, Dr. Mohamed highlighted ONC010's two selectivity mechanisms. The first is synthetic lethality, which is designed to limit the drug's lethality to cancer cells that have lost PTEN or SHP-1. The second is nanoparticle delivery, intended to concentrate the drug within tumor tissue. These mechanisms aim to enhance the drug's specificity and potentially reduce harm to healthy cells.
Dr. Mohamed also referenced preclinical research conducted at the University of Alberta. In that study, the nano-formulated PNKP inhibitor demonstrated single-agent antitumor activity, was tolerated at tested doses, and prolonged survival relative to controls. These findings provide early evidence of the drug's potential efficacy and safety profile.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company holds an exclusive worldwide licence to patented technology directed to the therapeutic inhibition of PNKP, a novel clinical target in DNA damage response. This licence positions Onco-Innovations to advance a potentially first-in-class therapy.
For investors and industry observers, the podcast and the underlying preclinical data underscore Onco-Innovations' progress in developing a targeted cancer therapy. If ONC010 succeeds in clinical trials, it could offer a new treatment option for cancers characterized by PTEN or SHP-1 loss, which are common in various malignancies. The synthetic lethality approach is particularly promising because it exploits specific genetic vulnerabilities in cancer cells, potentially leading to more personalized and effective treatments. The nanoparticle delivery system further aims to improve drug concentration at the tumor site, which could enhance efficacy and reduce systemic toxicity.
The planned first-in-human clinical program will be a critical step in translating these preclinical findings into a potential therapy for patients. Success in early-stage trials could attract further investment and partnerships, accelerating development. For the broader biotechnology and biomedical sectors, Onco-Innovations' work on PNKP inhibition adds to the growing body of research on DNA damage response targets, which are increasingly recognized as viable avenues for cancer therapy.
To view the full press release, visit https://ibn.fm/XgpMR. The latest news and updates relating to ONNVF are available in the company's newsroom at https://ibn.fm/ONNVF. BioMedWire is a specialized communications platform focused on the Biotechnology, Biomedical Sciences, and Life Sciences sectors. For more information, visit https://www.BioMedWire.com.
